Target Audience — Nurse practitioners, nurses and oncology social workers at the intermediate and advanced levels involved in the care of patients with hematologic malignancies.
Program Goal — To provide an interactive learning opportunity for oncology nurses, social workers and other healthcare professionals to expand their knowledge of treating patients with acute myeloid leukemia (AML).
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the role of genomics and other testing in diagnostic and treatment approaches for AML|
|•||Identify standard of care and new treatment approaches, including Beat AML® and other clinical trials for AML|
|•||Understand the central role of the HCP in assessment, monitoring for, and managing side effects of treatments|
|•||Provide resources for support of the patient and family throughout the treatment process|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurses, Nurse Practitioners, and Social Workers
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.
|Nurse Practitioner Credit Designation
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.08 hour(s) pharmacology) by the American Association of Nurse Practitioners. Activity ID# 18073263. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Social Worker Credit Designation
The Leukemia & Lymphoma Society (LLS), Provider Number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org. Approved Continuing Education Program (ACE). Approval period: 12/10/2017 – 12/14/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.5 CE clinical contact hours.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.5 CE clinical contact hours for this activity.
All faculty participating in continuing education activities supported by The Leukemia & Lymphoma Society are expected to disclose to the activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
James M. Foran, MD, FRCPC, is a Consultant for Jazz Pharmaceuticals and Novartis. He has also done research for Millennium: The Takeda Oncology Company.
Margaret Green, RN, OCN®, has no affiliations with commercial interests to disclose.
Darci L. Zblewski, APRN, C-NP, OCN®, has no affiliations with commercial interests to disclose.
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.